The Pulse Weekly Intelligence
|
Weekly Intelligence
The Pulse
Global Healthcare Intelligence
| July 25, 2026 |
Repligen’s $1.5B BioLife Deal Puts Cell-Therapy Infrastructure at the Center of Bioprocessing
Repligen agreed to acquire BioLife Solutions in a cash-and-stock transaction with an enterprise value of approximately $1.5 billion. BioLife adds biopreservation media, cell-processing tools, and recurring consumables used across the cell-therapy manufacturing chain. The combination is expected to close in the fourth quarter of 2026, subject to shareholder and regulatory approvals.
$1.5B Approximate enterprise value |
$31 Implied value per BioLife share |
Q4 Expected 2026 closing window |
As advanced therapies move toward commercialization, value is shifting beyond the therapeutic asset itself and toward the operational systems that make manufacturing repeatable and scalable.
| M&A · July 20 Tempus to Acquire Personalis, Deepening Its Precision-Oncology Platform Tempus AI entered a definitive agreement to acquire Personalis for approximately $1.5 billion. The deal combines Personalis’ minimal residual disease testing with Tempus’ multimodal data, AI, and commercial reach. $1.5B View announcement → |
Series D · July 22 Candid Health Raises $120M for Autonomous Revenue-Cycle Management Sixth Street Growth led the round, with participation from Oak HC/FT, 8VC, and Y Combinator. Candid said the financing tripled its valuation from its February 2025 Series C. $120M View funding news → |
| Series A · July 22 Assured Raises $19M to Automate Provider Credentialing and Enrollment Insight Partners led the financing for Assured’s AI-native provider-operations platform, with First Round Capital and Kindred Ventures participating. $19M Read coverage → |
Seed · July 22 Inner Logic Secures $11.5M for Procedural-Device Simulation The Johns Hopkins-founded company is building simulation infrastructure to help manufacturers design and validate intelligent procedural devices across virtual patients before physical testing. $11.5M View announcement → |
Capital Is Moving Toward the Less Visible Work of Healthcare
This week’s funding pattern was unusually consistent. Investors backed technology that addresses the administrative, validation, and operational layers behind care delivery—not simply another patient-facing application.
Candid targets billing. Assured targets credentialing. Inner Logic targets device validation. Tempus is integrating diagnostic monitoring into a broader precision-medicine platform. The common denominator is infrastructure that helps healthcare organizations act, scale, and measure.
| FDA · July 20 FDA Opens Digital Health Technologies Funding Opportunity The agency opened a funding opportunity through August 20 for selected applicants to explore digital health technologies—including actigraphy, photography, and contactless sensors—in drug development. Read FDA notice → |
NIH · July 22 NIH Launches Bio Genesis Mission NIH announced its component of the federal Genesis Mission, focused on combining AI, biomedical datasets, research infrastructure, and scientific expertise to accelerate discovery. Read NIH statement → |
The Tempus–Personalis agreement links recurrence monitoring with clinical data and AI at commercial scale.
Repligen’s BioLife acquisition brings preservation media and cell-processing tools into a broader bioprocessing platform.
Billing and credentialing platforms attracted $139 million in combined disclosed funding this week.
Inner Logic’s seed round highlights the growing need to validate autonomous and AI-enabled devices before clinical deployment.